ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
NCT ID: NCT06838676
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
60 participants
INTERVENTIONAL
2025-07-10
2035-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A
Patients with newly-diagnosed DIPG with typical MRI findings
ACT001
PO BID at 875 mg/m2 for 28 days
Cohort B
Patients with progressive/refractory/recurrent DIPG or extra-pontine H3K27-altered HGG tumors that have progressed following frontline treatment
ACT001
PO BID at 875 mg/m2 for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACT001
PO BID at 875 mg/m2 for 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis:
* Cohort A: Newly Diagnosed DIPG
* Patients with newly-diagnosed DIPG with typical MRI findings (tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons) with or without biopsy and have completed radiation therapy (RT) within 28 to 35 calendar day prior to start of therapy.
* Patients must have started RT \<42 calendar days of radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery, whichever is later. It is strongly recommended patients begin RT within 31 days of diagnosis/definitive surgery.
* If a biopsy was performed, the date of surgical biopsy will be considered the date of definitive diagnostic surgery; if a patient underwent two upfront surgeries \[e.g., biopsy then debulking\], this is the date of the second surgery)
* Patients must have received RT, but no other anti-cancer therapy other than surgery, and/or steroids prior to enrollment.
* Cohort B: progressive/refractory/recurrent DIPG or H3K27-altered HGG
* Patients with DIPG (no biopsy required) or pathologically-confirmed (at diagnosis or recurrence) extra-pontine H3K27-altered HGG who have progressive, refractory or recurrent disease following frontline treatment that included at least focal RT. Patients with refractory disease must have completed RT \>6 months prior to study enrollment.
* Patients with progressive disease only at the primary site(s) must have completed RT more than 3 months prior to enrollment.
* Patients with progressive disease only at the primary site(s) who completed radiation therapy 3 to 6 months prior to enrollment must have had at least one follow up MRI to confirm progression (rather than pseudo- progression)
* Patients with progressive disease due to the development a new metastatic site are eligible as long as eligibility criteria 3 (disease status) and 5 (prior RT) are met.
* Patients with metastatic disease are eligible.
3. Disease Status
* Cohort A: patients may have any disease status but must have completed initial radiation therapy (RT) before enrollment.
* Cohort B: Patients must have measurable disease assessable by MRI imaging. Patients may have metastatic disease. Lesions irradiated within the last 6 months are not considered measurable unless they show definitive progression following RT.
4. Performance Level: Karnofsky Performance Scale score ≥ 50% for patients \> 16 years of age and Lansky Performance Scale score \> 50% for patients ≤ 16 years of age (applies to all patients) Note: Patients who are unable to walk because of paralysis, but who are capable of using a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
5. Prior anti-cancer therapy:
* For Cohort A ONLY:
* Patients must not have received any prior therapy other than surgery, radiation (focal to disease) and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy).
* Patients must enroll and start treatment on study between 28 and 35 calendar days post-completion of RT.
* Patients must have started RT \<42 calendar days of initial diagnosis (defined as the date of diagnostic biopsy or resection; if a patient underwent two upfront surgeries \[e.g., biopsy then resection or debulking\], this is the date of the second surgery).
* Radiotherapy must have been administered at standard dose of 54 Gy for DIPG patients. Any variances in the radiotherapy dose within 10% of the standard doses outlined above will be discussed with the Study Chair (or their delegate) to confirm eligibility prior to study enrollment.
* For Cohort B ONLY: Patients must have fully recovered from adverse events due to prior treatment with investigational or conventional agents must have recovered to a severity of Grade 0 or Grade 1 (per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 or higher), with the exception of alopecia.
* Cohort A - Patients that have received any anti-cancer treatment other than RT are not eligible.
* Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.
* Anticonvulsants should be used as clinically indicated. The use of enzyme inducing anticonvulsants is not permitted
* LHRH agonist / antagonists are not permitted
* High Dose Biotin (B7) supplements are not permitted
3. Concomitant medications used with caution: selective serotonin reuptake inhibitor (SSRI) such as Lexapro, Fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), and escitalopram should be used with caution.
4. Infection: Patients who currently have an uncontrolled infection (in the opinion of the PI) are not eligible.
5. Patients who have received a prior solid organ transplantation are not eligible.
6. Pregnant or breast-feeding women will not be entered on this study due to unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are postmenarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
7. Patients of childbearing or child fathering potential must agree to use adequate contraceptive methods (hormonal or barrier method of birth control; abstinence) while being treated on this study and for 3 months after completing therapy. Note: The definition of effective contraception will be based on the judgement of the principal investigator or a designated associate.
8. Patients who are in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.
9. Patients who have previously received either ACT001 or parthenolide are not eligible.
Exclusion Criteria
1. Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).
2. Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor.
3. Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.
4. Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.
5. Monoclonal antibodies: \> 21 days must have elapsed from the infusion of last dose of antibody and toxicity related to antibody therapy must be recovered to Grade ≤ 1
6. Radiation therapy:
* For Cohort B, patients with refractory disease must have received their last fraction of frontline craniospinal or focal RT \> 6 months prior to study enrollment. Patients that have received re-irradiation for progression must have received their last fraction of focal radiation \>6 weeks or craniospinal radiation \>6 weeks prior to study enrollment.
7. Stem Cell Transplant: Patients must be ≥ 3 months since autologous stem cell transplant. Patients who received allogenic stem cell transplant or solid organ transplant are not eligible for study
6. Organ Function Requirements (applies to all patients)
1. Adequate bone marrow function defined as:
* Peripheral absolute neutrophil count (ANC) \> 1000/mm³
* Platelet count \> 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
2. Adequate renal function defined as:
* Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m² or
* A serum creatinine based on age/gender as follows (Schwartz et al. J. Peds, 106:522, 1985): Age Maximum Serum Creatinine (mg/dL) Male Female 1 to \< 2 years 0.6 0.6 2 to \< 6 years 0.8 0.8 6 to \< 10 years 1.0 1.0 10 to \< 13 years 1.2 1.2 13 to \< 16 years 1.5 1.4 ≥ 16 years 1.7 1.4
3. Adequate liver function defined as:
* total bilirubin within normal institutional limits
* AST (serum glutamic-oxaloacetic transaminase \[SGOT\]) / ALT (serum glutamic-oxaloacetic transaminase \[SGPT\]) ≤ 2.5 × institutional upper limit of normal
* Serum albumin ≥ 2 g/dL
4. Adequate cardiac function defined as:
* Ejection fraction of ≥ 50% by echocardiogram
* QTc ≤ 480 msec (by Bazett formula)
5. For Cohort B: Adequate neurologic function defined as:
* Patients with seizure disorders may be enrolled if seizures are well- controlled. Well controlled is defined by no increase in seizure frequency in the 7 days prior to enrollment.
* Patients with neurological deficits should have deficits that are stable for at least the 7 days prior to enrollment.
7. Informed Consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
8. Absence of other clinically significant concomitant active medical disorder, based on the investigator's judgement.
1. Cohort A only: Patients with metastatic disease.
2. Concomitant medications:
* Corticosteroids:
* Cohort A - Patients receiving corticosteroids are eligible regardless of dosing
* Cohort B - Patients receiving corticosteroids who have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are eligible
12 Months
39 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Accendatech USA Inc.
INDUSTRY
Nationwide Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David S. Ziegler, MD, FRACP
Role: STUDY_CHAIR
Sydney Children's Hospitals Network
Sara Khan, MD, PhD, FRACP
Role: STUDY_CHAIR
Nationwide Children's Hospital
Peter de Blank, MD, MSCE
Role: STUDY_CHAIR
Children's Hospital Medical Center, Cincinnati
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's National Medical Center
Washington D.C., District of Columbia, United States
Nicklaus Children's Hospital
Miami, Florida, United States
Emory University/Children's Healthcare of Atlanta
Atlanta, Georgia, United States
C.S. Mott Children's Hospital
Ann Arbor, Michigan, United States
St. Louis Children's Hospital
St Louis, Missouri, United States
Duke University Medical Center
Durham, North Carolina, United States
Cincinnati Children's Hospital
Cincinnati, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
Children's Hospital of Philidelphia
Philidelphia, Pennsylvania, United States
Texas Children's Hospital
Houston, Texas, United States
Seattle Children's Hospital
Seattle, Washington, United States
Sydney Children's Hospital
Randwick, New South Wales, Australia
Queensland Children's Hospital
South Brisbane, Queensland, Australia
Royal Children's Hospital
Melbourne, Victoria, Australia
Perth Children's Hospital
Perth, Western Australia, Australia
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada
Montreal Children's Hospital
Montreal, Quebec, Canada
Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)
Heidelberg, Baden-Wurttemberg, Germany
Starship Children's Hospital
Auckland, Grafton, New Zealand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eugene Hwang, MD
Role: primary
Ziad Khatib, MD
Role: primary
Tobey MacDonald, MD
Role: primary
Santhosh Upadhyaya, MBBS
Role: primary
Carl Koschmann, MD
Role: backup
Eric Thompson, MD
Role: primary
Mohamed Abdelbaki, MD
Role: backup
David Ashley, MBBS, FRACP, PhD
Role: primary
Daniel Landi, MD
Role: backup
Peter de Blank, MD
Role: primary
Sara Khan, MD
Role: primary
MIchael J Fisher, MD
Role: primary
Patricia Baxter, MD
Role: primary
Erin Crotty, MD
Role: primary
David Ziegler, MBBS, BSc, MD, PhD, FRACP
Role: primary
Tim Hassall, MBBS
Role: primary
David Eisenstat, MD
Role: primary
Nick Gottardo, MBChB, FRACP, PhD
Role: primary
Eric Bouffet, MD
Role: primary
Genevieve Legault, MD
Role: primary
Olaf Witt, MD
Role: primary
Sarah Hunter, MB ChB
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CONNECT2110
Identifier Type: -
Identifier Source: org_study_id